Beijing Science Sun Pharmaceutical Co., Ltd. (SHE:300485)
China · Delayed Price · Currency is CNY 10.30
+0.68 (7.07%)
Aug 20, 2026, 3:04 PM CST
SHE:300485 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 4,961 | 5,096 | 3,376 | 5,101 | 5,770 | 6,353 | |
Market Cap Growth | -29.06% | 50.93% | -33.80% | -11.60% | -9.17% | -10.64% |
Enterprise Value | 3,381 | 3,486 | 1,875 | 4,044 | 4,529 | 5,091 |
Last Close Price | 10.30 | 10.54 | 6.99 | 10.52 | 11.81 | 12.81 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | - | 349.74 | - | 49.56 | 28.19 | 15.79 |
Forward PE | - | 27.14 | 27.14 | 27.14 | 27.14 | 27.14 |
PS Ratio | 12.32 | 12.59 | 8.11 | 10.70 | 7.86 | 6.05 |
PB Ratio | 1.46 | 1.50 | 1.00 | 1.47 | 1.69 | 1.94 |
P/TBV Ratio | 1.50 | 1.54 | 1.03 | 1.52 | 1.75 | 2.01 |
P/FCF Ratio | - | - | 96.89 | - | 85.93 | 46.25 |
P/OCF Ratio | 181.42 | 188.19 | 24.83 | 240.48 | 52.25 | 34.66 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 8.40 | 8.61 | 4.50 | 8.49 | 6.17 | 4.85 |
EV/EBITDA Ratio | 87.21 | 117.54 | 27.03 | 468.15 | 63.22 | 33.70 |
EV/EBIT Ratio | - | - | 83.53 | - | 186.82 | 53.36 |
EV/FCF Ratio | - | - | 53.80 | - | 67.45 | 37.06 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.01 | 0.01 | - | - | - | - |
Debt / EBITDA Ratio | 0.51 | 0.66 | - | - | - | - |
Net Debt / Equity Ratio | -0.47 | -0.45 | -0.46 | -0.34 | -0.33 | -0.39 |
Net Debt / EBITDA Ratio | -41.69 | -52.00 | -22.66 | -135.86 | -15.66 | -8.58 |
Net Debt / FCF Ratio | 22.21 | 21.07 | -45.10 | 37.02 | -16.70 | -9.43 |
Asset Turnover | 0.11 | 0.11 | 0.12 | 0.13 | 0.21 | 0.33 |
Inventory Turnover | 1.80 | 1.97 | 1.52 | 1.44 | 1.62 | 1.29 |
Quick Ratio | 19.07 | 17.42 | 19.79 | 23.91 | 16.15 | 15.75 |
Current Ratio | 20.09 | 18.28 | 20.86 | 26.30 | 17.62 | 17.30 |
Return on Equity (ROE) | -0.80% | 0.23% | -2.24% | 2.80% | 6.05% | 12.88% |
Return on Assets (ROA) | -0.15% | -0.30% | 0.39% | -0.69% | 0.43% | 1.86% |
Return on Invested Capital (ROIC) | -0.47% | -0.60% | 1.09% | -1.37% | 0.90% | 4.70% |
Return on Capital Employed (ROCE) | -0.20% | -0.50% | 0.60% | -1.10% | 0.70% | 2.90% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | -0.42% | 0.29% | -2.04% | 2.02% | 3.55% | 6.33% |
FCF Yield | -1.45% | -1.44% | 1.03% | -0.62% | 1.16% | 2.16% |
Dividend Yield | 3.12% | 2.84% | - | 0.21% | 0.73% | 1.31% |
Payout Ratio | - | 1.72% | - | 40.22% | 39.50% | 7.78% |
Buyback Yield / Dilution | 1.28% | 1.24% | -0.35% | -2.93% | 0.58% | 1.07% |
Total Shareholder Return | 4.31% | 4.09% | -0.35% | -2.72% | 1.31% | 2.38% |